Related Experiment Video
Updated: Jun 23, 2026
07:50
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
The correlation between GPR30 and clinicopathologic variables in breast carcinomas
1Department of General Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.
Technology in Cancer Research & Treatment
|May 19, 2009
Summary
G-protein-coupled-receptor 30 (GPR30), a novel estrogen receptor, shows a weak negative correlation with estrogen receptor alpha and progesterone receptor in breast cancer. GPR30 may serve as an independent prognostic factor for breast carcinomas.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Background:
- G-protein-coupled-receptor 30 (GPR30) is identified as a novel membrane estrogen receptor.
- Understanding GPR30's role in breast cancer is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the correlations between GPR30 and established breast cancer biomarkers.
- To assess GPR30's relationship with clinicopathological features like TNM stage and tumor grade.
Main Methods:
- Immunohistochemical analysis of 241 breast carcinoma biopsy specimens.
- Statistical analysis to determine correlations between GPR30, ERalpha, PR, C-erbB-2, p53, TNM stage, and pathologic grade.
Main Results:
- A low negative correlation was observed between GPR30 and ERalpha (r = -0.144, P<0.05).
- A low negative correlation was observed between GPR30 and PR (r = -0.214, P<0.01).
- No significant associations were found between GPR30 and C-erbB-2, p53, TNM stage, or pathologic grade.
Conclusions:
- GPR30 expression is weakly inversely correlated with ERalpha and PR in breast carcinomas.
- GPR30 may function as an independent prognostic indicator in breast cancer patients.